NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Five charged in U.S. with stealing secrets from GlaxoSmithKline

Published 20/01/2016, 22:58
© Reuters. The signage for the GlaxoSmithKline building is pictured in London
GSK
-

By Bill Berkrot

(Reuters) - Five people, including two former GlaxoSmithKline (L:GSK) researchers, were charged with a scheme to steal trade secrets from the British drugmaker for potential sale in China, according to indictments announced by the U.S. Attorney's Office in Philadelphia on Wednesday.

The indictments include charges of conspiracy to steal trade secrets, conspiracy to commit wire fraud, conspiracy to commit money laundering, theft of trade secrets, and wire fraud.

The stolen information on drugs for cancer and other serious diseases "potentially could be sold for millions of dollars to rival pharmaceutical companies and it would also be useful information for a start-up pharmaceutical company," the complaint said.

The alleged conspirators established three corporations in China, all using the name Renopharma, to sell the stolen information that could be used to reproduce Glaxo products and drugs in development, to competitors in China, according to the complaint.

One of the five, Yu Xue, was a senior-level manager and biotechnology expert at a Glaxo research facility in Pennsylvania with access to a wide array of secret information. She was fired Jan. 6, Glaxo said.

She is accused of sending confidential information related to a dozen or more products to fellow "conspirators and others," and also downloading a substantial amount of Glaxo intellectual property to pass along as part of the alleged scheme.

A motion aimed at keeping Yu Xue detained that was filed earlier this month said she "stole millions, perhaps billions, of dollars' worth of trade secret and other confidential information from her employer, GlaxoSmithKline, to resell in China."

"Ms. Xue denies these allegations. She has pled not guilty and intends to contest these charges vigorously in court," her attorney Peter Zeidenberg of Arent Fox said in an emailed statement.

The others named were Lucy Xi, a Glaxo scientist who left the company in November, Tao Li, Yan Mei and Tian Xue, who is Yu Xue's twin sister. The sister was used to hide proceeds of the crime, according to the complaint.

Mei is still being sought by authorities. Tao Li remains in custody, while the other three were arrested and released on bail, a spokeswoman for the U.S. Attorney's office said.

Glaxo said it has been cooperating with authorities. "We do not believe the breach has had any material impact on the company's business or R&D activity," it said in a statement.

© Reuters. The signage for the GlaxoSmithKline building is pictured in London

The alleged crimes took place between Jan. 1, 2012 and Dec. 28, 2015, the complaint said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.